Last reviewed · How we verify
Teriparatide (Forteo)
Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling.
Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling. Used for Osteoporosis in postmenopausal women at high risk for fracture, Osteoporosis in men at high risk for fracture, Glucocorticoid-induced osteoporosis.
At a glance
| Generic name | Teriparatide (Forteo) |
|---|---|
| Also known as | Forteo, PTH, Parathyroid Hormone, FORTEO |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Parathyroid hormone analog |
| Target | PTH1 receptor (parathyroid hormone 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Bone Metabolism |
| Phase | FDA-approved |
Mechanism of action
Teriparatide mimics the action of endogenous parathyroid hormone (PTH) by binding to PTH1 receptors on osteoblasts, promoting bone cell proliferation and differentiation. This leads to increased bone turnover with a net gain in bone mass, particularly in trabecular bone. Unlike other osteoporosis agents that primarily inhibit bone resorption, teriparatide actively stimulates new bone formation.
Approved indications
- Osteoporosis in postmenopausal women at high risk for fracture
- Osteoporosis in men at high risk for fracture
- Glucocorticoid-induced osteoporosis
Common side effects
- Injection site reactions (erythema, pain, swelling)
- Nausea
- Dizziness
- Headache
- Leg cramps
- Hypercalcemia
Key clinical trials
- A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants (PHASE1)
- Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo (PHASE1)
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
- Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury (PHASE2)
- Effect of Mechanical Loading With PTH on Cortical Bone (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid (PHASE4)
- Novel Combination Therapy for Osteoporosis in Men (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teriparatide (Forteo) CI brief — competitive landscape report
- Teriparatide (Forteo) updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI